| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Central Nervous System Neoplasms | 66 | 2023 | 895 | 11.480 |
Why?
|
| Brain Neoplasms | 167 | 2024 | 8861 | 7.370 |
Why?
|
| Lymphoma | 44 | 2023 | 1877 | 6.640 |
Why?
|
| Glioblastoma | 95 | 2024 | 3481 | 6.360 |
Why?
|
| Lymphoma, Non-Hodgkin | 32 | 2021 | 1381 | 6.350 |
Why?
|
| Glioma | 72 | 2023 | 3401 | 4.840 |
Why?
|
| Angiogenesis Inhibitors | 32 | 2021 | 2038 | 2.790 |
Why?
|
| Isocitrate Dehydrogenase | 19 | 2023 | 871 | 2.580 |
Why?
|
| Methotrexate | 25 | 2023 | 1728 | 2.410 |
Why?
|
| Quinazolines | 25 | 2017 | 1356 | 2.350 |
Why?
|
| Antimetabolites, Antineoplastic | 17 | 2015 | 640 | 2.080 |
Why?
|
| Dacarbazine | 22 | 2017 | 566 | 2.030 |
Why?
|
| Neovascularization, Pathologic | 20 | 2017 | 2638 | 2.000 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 11 | 2022 | 1378 | 1.960 |
Why?
|
| Neoplasm Recurrence, Local | 46 | 2023 | 9240 | 1.950 |
Why?
|
| Antineoplastic Agents, Alkylating | 21 | 2020 | 627 | 1.910 |
Why?
|
| Antineoplastic Agents | 54 | 2020 | 13693 | 1.860 |
Why?
|
| Nervous System Neoplasms | 6 | 2018 | 91 | 1.790 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 33 | 2021 | 11525 | 1.520 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 15 | 2017 | 664 | 1.420 |
Why?
|
| Glutarates | 10 | 2021 | 236 | 1.410 |
Why?
|
| Cranial Irradiation | 8 | 2021 | 401 | 1.220 |
Why?
|
| Combined Modality Therapy | 34 | 2023 | 8642 | 1.110 |
Why?
|
| Neurotoxicity Syndromes | 6 | 2023 | 290 | 1.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 16 | 2018 | 3511 | 1.090 |
Why?
|
| Paraneoplastic Syndromes | 5 | 2022 | 151 | 1.080 |
Why?
|
| Vascular Endothelial Growth Factors | 3 | 2013 | 772 | 1.030 |
Why?
|
| Salvage Therapy | 8 | 2019 | 1275 | 0.960 |
Why?
|
| Stem Cell Transplantation | 7 | 2018 | 1620 | 0.940 |
Why?
|
| Mutation | 43 | 2024 | 29786 | 0.820 |
Why?
|
| Radiotherapy | 10 | 2019 | 1533 | 0.810 |
Why?
|
| Humans | 307 | 2024 | 744366 | 0.800 |
Why?
|
| Capillary Permeability | 2 | 2019 | 798 | 0.790 |
Why?
|
| Epidural Neoplasms | 3 | 2016 | 24 | 0.780 |
Why?
|
| Disease-Free Survival | 34 | 2020 | 6896 | 0.760 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2019 | 705 | 0.760 |
Why?
|
| Magnetic Resonance Spectroscopy | 8 | 2021 | 3759 | 0.740 |
Why?
|
| Prognosis | 46 | 2021 | 29060 | 0.720 |
Why?
|
| Protein Kinase Inhibitors | 11 | 2024 | 5534 | 0.670 |
Why?
|
| Meningeal Neoplasms | 11 | 2017 | 1241 | 0.660 |
Why?
|
| Brain Edema | 6 | 2009 | 617 | 0.640 |
Why?
|
| Brain | 30 | 2023 | 26388 | 0.610 |
Why?
|
| Maximum Tolerated Dose | 10 | 2020 | 892 | 0.570 |
Why?
|
| Magnetic Resonance Imaging | 56 | 2021 | 35425 | 0.570 |
Why?
|
| Myeloid Differentiation Factor 88 | 3 | 2021 | 571 | 0.560 |
Why?
|
| Nervous System Diseases | 4 | 2022 | 1622 | 0.560 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2017 | 187 | 0.550 |
Why?
|
| Brain Diseases | 3 | 2019 | 1563 | 0.520 |
Why?
|
| Critical Pathways | 1 | 2019 | 476 | 0.500 |
Why?
|
| Survival Rate | 26 | 2020 | 12788 | 0.490 |
Why?
|
| Middle Aged | 119 | 2022 | 213390 | 0.490 |
Why?
|
| Aged | 100 | 2023 | 163288 | 0.480 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2023 | 5445 | 0.470 |
Why?
|
| Blood-Brain Barrier | 7 | 2019 | 1019 | 0.470 |
Why?
|
| Neoplasm Proteins | 6 | 2021 | 3707 | 0.470 |
Why?
|
| Eye Neoplasms | 4 | 2008 | 312 | 0.470 |
Why?
|
| Nose Neoplasms | 1 | 2016 | 246 | 0.460 |
Why?
|
| Male | 137 | 2022 | 350115 | 0.460 |
Why?
|
| Biostatistics | 1 | 2015 | 161 | 0.450 |
Why?
|
| Astrocytoma | 6 | 2013 | 790 | 0.450 |
Why?
|
| Clinical Trials as Topic | 17 | 2023 | 7914 | 0.450 |
Why?
|
| Parietal Lobe | 2 | 2016 | 838 | 0.440 |
Why?
|
| Central Nervous System | 7 | 2022 | 1357 | 0.440 |
Why?
|
| Female | 140 | 2021 | 380193 | 0.430 |
Why?
|
| Adult | 110 | 2022 | 214052 | 0.420 |
Why?
|
| Pyridines | 9 | 2021 | 2825 | 0.420 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 3 | 2014 | 693 | 0.420 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2016 | 524 | 0.410 |
Why?
|
| Cranial Nerves | 1 | 2012 | 101 | 0.410 |
Why?
|
| Treatment Outcome | 52 | 2023 | 63107 | 0.410 |
Why?
|
| Enzyme Inhibitors | 4 | 2018 | 3799 | 0.410 |
Why?
|
| Vitreous Body | 3 | 2021 | 389 | 0.400 |
Why?
|
| Polyneuropathies | 1 | 2012 | 137 | 0.390 |
Why?
|
| Transplantation, Autologous | 7 | 2023 | 2124 | 0.380 |
Why?
|
| DNA Modification Methylases | 6 | 2013 | 206 | 0.370 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 2 | 2009 | 85 | 0.370 |
Why?
|
| Disease Progression | 28 | 2019 | 13286 | 0.360 |
Why?
|
| Camptothecin | 4 | 2009 | 576 | 0.360 |
Why?
|
| Immunologic Factors | 1 | 2019 | 1580 | 0.350 |
Why?
|
| Headache | 3 | 2015 | 1226 | 0.340 |
Why?
|
| DNA Repair Enzymes | 6 | 2013 | 349 | 0.340 |
Why?
|
| Lymphoma, T-Cell | 3 | 2019 | 299 | 0.330 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 4 | 2018 | 2737 | 0.330 |
Why?
|
| Neoplasms | 11 | 2023 | 21696 | 0.330 |
Why?
|
| Peripheral Nerves | 1 | 2012 | 466 | 0.330 |
Why?
|
| Lymphoma, B-Cell | 4 | 2006 | 931 | 0.310 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2018 | 5172 | 0.310 |
Why?
|
| Phthalazines | 1 | 2010 | 363 | 0.310 |
Why?
|
| Gene Amplification | 5 | 2016 | 1063 | 0.310 |
Why?
|
| Oligodendroglioma | 4 | 2019 | 279 | 0.310 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2019 | 4424 | 0.310 |
Why?
|
| Piperidines | 5 | 2019 | 1602 | 0.300 |
Why?
|
| Piperazines | 2 | 2021 | 2488 | 0.300 |
Why?
|
| Hypertensive Encephalopathy | 1 | 2007 | 9 | 0.300 |
Why?
|
| Cytarabine | 7 | 2017 | 692 | 0.300 |
Why?
|
| Disease Management | 5 | 2019 | 2460 | 0.300 |
Why?
|
| Topotecan | 1 | 2007 | 137 | 0.300 |
Why?
|
| Drug Administration Schedule | 9 | 2018 | 4933 | 0.290 |
Why?
|
| Aged, 80 and over | 36 | 2021 | 57776 | 0.290 |
Why?
|
| Burkitt Lymphoma | 2 | 2019 | 327 | 0.280 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2019 | 475 | 0.280 |
Why?
|
| Diagnostic Imaging | 5 | 2014 | 3508 | 0.280 |
Why?
|
| Hypoglossal Nerve | 2 | 1997 | 95 | 0.270 |
Why?
|
| Hodgkin Disease | 2 | 2008 | 1415 | 0.270 |
Why?
|
| Positron-Emission Tomography | 4 | 2021 | 6234 | 0.270 |
Why?
|
| Neoplasm Staging | 13 | 2020 | 11031 | 0.270 |
Why?
|
| Morpholines | 2 | 2019 | 571 | 0.260 |
Why?
|
| Nerve Sheath Neoplasms | 2 | 2005 | 191 | 0.260 |
Why?
|
| Tumor Suppressor Proteins | 7 | 2017 | 2850 | 0.260 |
Why?
|
| Blood Vessels | 4 | 2014 | 1125 | 0.260 |
Why?
|
| Ribonuclease, Pancreatic | 2 | 2016 | 154 | 0.260 |
Why?
|
| Tumor Microenvironment | 8 | 2023 | 3590 | 0.260 |
Why?
|
| Radiation Injuries | 3 | 2019 | 1180 | 0.260 |
Why?
|
| Paralysis | 2 | 1997 | 247 | 0.260 |
Why?
|
| Retinal Neoplasms | 2 | 2021 | 144 | 0.260 |
Why?
|
| Survival Analysis | 17 | 2023 | 10252 | 0.260 |
Why?
|
| Aminopyridines | 2 | 2019 | 542 | 0.260 |
Why?
|
| Bayes Theorem | 5 | 2023 | 2307 | 0.250 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2019 | 890 | 0.250 |
Why?
|
| Image Processing, Computer-Assisted | 8 | 2019 | 8949 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 16 | 2020 | 6539 | 0.250 |
Why?
|
| Leukemia, Plasma Cell | 1 | 2004 | 48 | 0.250 |
Why?
|
| Antibodies, Neoplasm | 2 | 2016 | 286 | 0.250 |
Why?
|
| Oligodendroglia | 2 | 2018 | 517 | 0.240 |
Why?
|
| Snake Venoms | 2 | 2015 | 39 | 0.240 |
Why?
|
| Plasmacytoma | 1 | 2004 | 183 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2020 | 10943 | 0.230 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2020 | 3554 | 0.230 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2023 | 1271 | 0.230 |
Why?
|
| Young Adult | 33 | 2020 | 56429 | 0.230 |
Why?
|
| Diagnosis, Differential | 10 | 2019 | 12961 | 0.230 |
Why?
|
| Neoplasm Metastasis | 5 | 2020 | 4851 | 0.230 |
Why?
|
| Cyclophosphamide | 7 | 2019 | 2242 | 0.230 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 1832 | 0.220 |
Why?
|
| Medical Oncology | 3 | 2018 | 2267 | 0.220 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2022 | 20130 | 0.220 |
Why?
|
| Receptors, Dopamine D5 | 2 | 2020 | 32 | 0.220 |
Why?
|
| Meningitis | 1 | 2004 | 216 | 0.220 |
Why?
|
| DNA Methylation | 6 | 2019 | 4285 | 0.210 |
Why?
|
| Preventive Medicine | 1 | 2004 | 264 | 0.210 |
Why?
|
| Meningioma | 3 | 2017 | 1209 | 0.210 |
Why?
|
| Neoplastic Stem Cells | 3 | 2017 | 1376 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2023 | 17446 | 0.210 |
Why?
|
| Paraproteinemias | 1 | 2004 | 246 | 0.210 |
Why?
|
| Chemotherapy, Adjuvant | 11 | 2019 | 3480 | 0.210 |
Why?
|
| Thalidomide | 5 | 2019 | 890 | 0.210 |
Why?
|
| Oxygen | 1 | 2013 | 4189 | 0.200 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 3 | 2017 | 86 | 0.200 |
Why?
|
| Molecular Targeted Therapy | 6 | 2019 | 2725 | 0.200 |
Why?
|
| Pyrimidines | 5 | 2020 | 2943 | 0.200 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2020 | 4042 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 10 | 3 | 2009 | 287 | 0.200 |
Why?
|
| Recurrence | 6 | 2012 | 8340 | 0.190 |
Why?
|
| Imidazoles | 4 | 2020 | 1206 | 0.190 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2021 | 45 | 0.190 |
Why?
|
| Inositol | 1 | 2021 | 218 | 0.190 |
Why?
|
| Neoplasms, Experimental | 2 | 2016 | 1276 | 0.190 |
Why?
|
| Quinolines | 2 | 2016 | 732 | 0.190 |
Why?
|
| Terminology as Topic | 2 | 2018 | 1547 | 0.190 |
Why?
|
| Cell Line, Tumor | 13 | 2019 | 16690 | 0.190 |
Why?
|
| Pyrazoles | 5 | 2019 | 1972 | 0.190 |
Why?
|
| Stress, Physiological | 2 | 2019 | 1403 | 0.180 |
Why?
|
| Hexokinase | 1 | 2020 | 124 | 0.180 |
Why?
|
| Hydroxamic Acids | 2 | 2015 | 494 | 0.180 |
Why?
|
| Spinal Cord Neoplasms | 2 | 2014 | 281 | 0.180 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2015 | 1771 | 0.180 |
Why?
|
| Follow-Up Studies | 21 | 2019 | 39052 | 0.180 |
Why?
|
| Corpus Callosum | 1 | 2005 | 737 | 0.180 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2013 | 629 | 0.180 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2020 | 65 | 0.180 |
Why?
|
| Oncolytic Viruses | 1 | 2023 | 327 | 0.170 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2019 | 2110 | 0.170 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2017 | 170 | 0.170 |
Why?
|
| Gene Deletion | 2 | 2005 | 2751 | 0.170 |
Why?
|
| Histones | 5 | 2023 | 2598 | 0.170 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2019 | 85 | 0.170 |
Why?
|
| Transcription Factor RelA | 1 | 2020 | 275 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 19 | 3 | 2005 | 367 | 0.170 |
Why?
|
| Vincristine | 2 | 2019 | 1039 | 0.170 |
Why?
|
| Tissue Distribution | 3 | 2017 | 2327 | 0.170 |
Why?
|
| Anticonvulsants | 7 | 2010 | 1916 | 0.170 |
Why?
|
| Biopsy | 6 | 2019 | 6755 | 0.170 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2018 | 1375 | 0.170 |
Why?
|
| Retrospective Studies | 31 | 2023 | 77460 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 323 | 0.160 |
Why?
|
| Drug Delivery Systems | 3 | 2018 | 2219 | 0.160 |
Why?
|
| Neurosciences | 1 | 2023 | 348 | 0.160 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2018 | 45 | 0.160 |
Why?
|
| Cyanides | 1 | 2018 | 83 | 0.160 |
Why?
|
| Transplantation Conditioning | 3 | 2017 | 1599 | 0.160 |
Why?
|
| Immunohistochemistry | 11 | 2018 | 11366 | 0.160 |
Why?
|
| NAD | 3 | 2017 | 590 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2005 | 658 | 0.160 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2019 | 130 | 0.160 |
Why?
|
| Animals | 31 | 2020 | 168768 | 0.160 |
Why?
|
| Endothelial Cells | 3 | 2023 | 3486 | 0.160 |
Why?
|
| Herpesvirus 1, Human | 1 | 2023 | 743 | 0.160 |
Why?
|
| Oncolytic Virotherapy | 1 | 2023 | 498 | 0.160 |
Why?
|
| Signal Transduction | 14 | 2020 | 23404 | 0.150 |
Why?
|
| Lomustine | 2 | 2017 | 59 | 0.150 |
Why?
|
| Neurosecretory Systems | 1 | 2019 | 231 | 0.150 |
Why?
|
| Ketoglutarate Dehydrogenase Complex | 1 | 2017 | 20 | 0.150 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2016 | 1624 | 0.150 |
Why?
|
| Guanidines | 1 | 2018 | 193 | 0.150 |
Why?
|
| Macrophages | 4 | 2017 | 5660 | 0.150 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2017 | 91 | 0.150 |
Why?
|
| Chorea | 1 | 1998 | 74 | 0.150 |
Why?
|
| Indoles | 3 | 2015 | 1839 | 0.150 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2014 | 1524 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 6 | 2013 | 6171 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2018 | 8432 | 0.150 |
Why?
|
| Karnofsky Performance Status | 3 | 2015 | 173 | 0.150 |
Why?
|
| Tongue | 2 | 1997 | 406 | 0.150 |
Why?
|
| Mental Status Schedule | 2 | 2011 | 321 | 0.150 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2018 | 934 | 0.140 |
Why?
|
| Hydroxyurea | 1 | 2018 | 289 | 0.140 |
Why?
|
| Models, Biological | 5 | 2016 | 9584 | 0.140 |
Why?
|
| In Situ Hybridization, Fluorescence | 6 | 2014 | 2649 | 0.140 |
Why?
|
| Lung Neoplasms | 4 | 2024 | 13104 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2020 | 9955 | 0.140 |
Why?
|
| NADP | 1 | 2017 | 226 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2004 | 2949 | 0.140 |
Why?
|
| Tongue Diseases | 1 | 1996 | 67 | 0.140 |
Why?
|
| Tumor Escape | 1 | 2019 | 350 | 0.140 |
Why?
|
| Mice, SCID | 5 | 2020 | 2716 | 0.140 |
Why?
|
| DNA-Binding Proteins | 5 | 2008 | 9647 | 0.140 |
Why?
|
| Muscle Weakness | 2 | 2015 | 413 | 0.130 |
Why?
|
| Gene Expression Profiling | 7 | 2015 | 9445 | 0.130 |
Why?
|
| Thiotepa | 4 | 2017 | 66 | 0.130 |
Why?
|
| Phenylurea Compounds | 2 | 2016 | 528 | 0.130 |
Why?
|
| Blood Volume Determination | 1 | 2015 | 43 | 0.130 |
Why?
|
| Lithium | 1 | 2019 | 601 | 0.130 |
Why?
|
| Procarbazine | 2 | 2006 | 181 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2019 | 2504 | 0.130 |
Why?
|
| Toll-Like Receptors | 1 | 2019 | 593 | 0.130 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2013 | 1443 | 0.130 |
Why?
|
| Cognition Disorders | 4 | 2016 | 4043 | 0.130 |
Why?
|
| Postoperative Care | 2 | 2019 | 1487 | 0.130 |
Why?
|
| Administration, Oral | 4 | 2017 | 3914 | 0.130 |
Why?
|
| Testicular Neoplasms | 1 | 2001 | 806 | 0.130 |
Why?
|
| Rhabdoid Tumor | 1 | 2017 | 212 | 0.130 |
Why?
|
| Algorithms | 6 | 2024 | 13882 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 3 | 2019 | 2727 | 0.130 |
Why?
|
| Colonic Neoplasms | 1 | 2007 | 2542 | 0.130 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2017 | 648 | 0.120 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2016 | 2943 | 0.120 |
Why?
|
| Oncogenes | 2 | 2018 | 1265 | 0.120 |
Why?
|
| Busulfan | 4 | 2017 | 263 | 0.120 |
Why?
|
| B-Lymphocytes | 2 | 2021 | 4666 | 0.120 |
Why?
|
| Leukemia | 2 | 2015 | 1510 | 0.120 |
Why?
|
| Hemangioblastoma | 1 | 2014 | 70 | 0.120 |
Why?
|
| Loss of Heterozygosity | 2 | 2009 | 684 | 0.120 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 3 | 2015 | 547 | 0.120 |
Why?
|
| Gene Dosage | 1 | 2019 | 1252 | 0.120 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2017 | 449 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2016 | 730 | 0.120 |
Why?
|
| Adolescent | 20 | 2019 | 85779 | 0.120 |
Why?
|
| Wnt Proteins | 1 | 2018 | 721 | 0.120 |
Why?
|
| Endpoint Determination | 2 | 2008 | 601 | 0.120 |
Why?
|
| Antibodies, Bispecific | 1 | 2016 | 164 | 0.120 |
Why?
|
| Etoposide | 2 | 2013 | 641 | 0.120 |
Why?
|
| Neurosurgical Procedures | 3 | 2019 | 2002 | 0.120 |
Why?
|
| NF-kappa B | 2 | 2020 | 2499 | 0.120 |
Why?
|
| Image Interpretation, Computer-Assisted | 4 | 2020 | 3326 | 0.120 |
Why?
|
| Immunocompromised Host | 1 | 2019 | 847 | 0.110 |
Why?
|
| Adenine | 1 | 2019 | 936 | 0.110 |
Why?
|
| Neoplasm, Residual | 1 | 2018 | 973 | 0.110 |
Why?
|
| Receptors, CXCR4 | 1 | 2018 | 727 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 3873 | 0.110 |
Why?
|
| Drug Antagonism | 1 | 2013 | 50 | 0.110 |
Why?
|
| Vesicular Transport Proteins | 1 | 2016 | 377 | 0.110 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2014 | 290 | 0.110 |
Why?
|
| Age Factors | 5 | 2019 | 18373 | 0.110 |
Why?
|
| Cohort Studies | 14 | 2022 | 40559 | 0.110 |
Why?
|
| Fatal Outcome | 3 | 2012 | 1851 | 0.110 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 2540 | 0.110 |
Why?
|
| Polyradiculopathy | 1 | 2012 | 23 | 0.110 |
Why?
|
| International Agencies | 1 | 2013 | 240 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 5 | 2019 | 6313 | 0.110 |
Why?
|
| Somatostatin | 1 | 2014 | 459 | 0.110 |
Why?
|
| Radiosurgery | 2 | 2020 | 1329 | 0.110 |
Why?
|
| Muscular Diseases | 1 | 1997 | 555 | 0.110 |
Why?
|
| Natural Killer T-Cells | 1 | 2016 | 316 | 0.110 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2016 | 903 | 0.110 |
Why?
|
| Prospective Studies | 11 | 2022 | 53290 | 0.100 |
Why?
|
| Injections, Spinal | 4 | 2007 | 303 | 0.100 |
Why?
|
| Peripheral Nervous System Neoplasms | 2 | 2005 | 122 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2017 | 3773 | 0.100 |
Why?
|
| Contrast Media | 4 | 2018 | 5300 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2013 | 2043 | 0.100 |
Why?
|
| Dexamethasone | 2 | 2011 | 1951 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2014 | 551 | 0.100 |
Why?
|
| Mutation, Missense | 2 | 2021 | 2566 | 0.100 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2011 | 323 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2018 | 956 | 0.100 |
Why?
|
| Likelihood Functions | 1 | 2015 | 1005 | 0.100 |
Why?
|
| Palliative Care | 1 | 2006 | 3493 | 0.100 |
Why?
|
| Gene Expression | 4 | 2018 | 7798 | 0.100 |
Why?
|
| Nausea | 3 | 2020 | 674 | 0.100 |
Why?
|
| DNA Replication | 1 | 2018 | 1399 | 0.100 |
Why?
|
| Genotype | 4 | 2023 | 12952 | 0.100 |
Why?
|
| Mice | 17 | 2020 | 81201 | 0.100 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 2887 | 0.100 |
Why?
|
| Fixatives | 1 | 2010 | 94 | 0.100 |
Why?
|
| Interferon Inducers | 1 | 2010 | 25 | 0.100 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 169 | 0.100 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2010 | 126 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2014 | 713 | 0.090 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2010 | 39 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2016 | 988 | 0.090 |
Why?
|
| Epothilones | 1 | 2010 | 44 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2003 | 4554 | 0.090 |
Why?
|
| Leukemic Infiltration | 1 | 2010 | 48 | 0.090 |
Why?
|
| Poly I-C | 1 | 2010 | 115 | 0.090 |
Why?
|
| Remission Induction | 3 | 2017 | 2385 | 0.090 |
Why?
|
| Mice, Nude | 4 | 2020 | 3689 | 0.090 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 675 | 0.090 |
Why?
|
| Polylysine | 1 | 2010 | 133 | 0.090 |
Why?
|
| Receptor, TIE-2 | 1 | 2010 | 178 | 0.090 |
Why?
|
| Dimethylnitrosamine | 1 | 2009 | 16 | 0.090 |
Why?
|
| Bone Marrow Cells | 1 | 2017 | 2513 | 0.090 |
Why?
|
| Aniline Compounds | 1 | 2014 | 986 | 0.090 |
Why?
|
| Neurology | 1 | 2018 | 763 | 0.090 |
Why?
|
| Cerebellar Neoplasms | 1 | 2014 | 587 | 0.090 |
Why?
|
| Paraffin Embedding | 1 | 2010 | 299 | 0.090 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2016 | 570 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2019 | 4222 | 0.090 |
Why?
|
| Nitriles | 1 | 2014 | 955 | 0.090 |
Why?
|
| Necrosis | 4 | 2019 | 1643 | 0.090 |
Why?
|
| Bone Marrow Transplantation | 1 | 2017 | 2765 | 0.090 |
Why?
|
| Nitrosamines | 1 | 2009 | 87 | 0.090 |
Why?
|
| Methylation | 1 | 2012 | 1106 | 0.090 |
Why?
|
| Quality of Life | 9 | 2019 | 12802 | 0.080 |
Why?
|
| Radiography | 4 | 2014 | 7023 | 0.080 |
Why?
|
| Nitrites | 1 | 2009 | 160 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2019 | 2938 | 0.080 |
Why?
|
| Melanoma | 2 | 2019 | 5511 | 0.080 |
Why?
|
| Formaldehyde | 1 | 2010 | 353 | 0.080 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 6773 | 0.080 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2009 | 180 | 0.080 |
Why?
|
| World Health Organization | 3 | 2021 | 1318 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 3 | 2010 | 9274 | 0.080 |
Why?
|
| Regeneration | 1 | 2017 | 1485 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2013 | 1660 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2022 | 3595 | 0.080 |
Why?
|
| Head | 1 | 2014 | 880 | 0.080 |
Why?
|
| Cancer Vaccines | 1 | 2016 | 1023 | 0.080 |
Why?
|
| Hematologic Tests | 1 | 2009 | 240 | 0.080 |
Why?
|
| Consensus | 4 | 2021 | 2960 | 0.080 |
Why?
|
| Skin Neoplasms | 2 | 2019 | 5692 | 0.080 |
Why?
|
| Myeloid Cells | 1 | 2013 | 810 | 0.080 |
Why?
|
| Nitrates | 1 | 2009 | 265 | 0.080 |
Why?
|
| Pyrroles | 1 | 2014 | 1146 | 0.080 |
Why?
|
| Research Design | 3 | 2013 | 5984 | 0.080 |
Why?
|
| Point Mutation | 1 | 2013 | 1624 | 0.080 |
Why?
|
| Patient Selection | 3 | 2016 | 4216 | 0.080 |
Why?
|
| Phenytoin | 1 | 2008 | 197 | 0.070 |
Why?
|
| Image Enhancement | 1 | 2018 | 2921 | 0.070 |
Why?
|
| Ependymoma | 1 | 2010 | 334 | 0.070 |
Why?
|
| Sirolimus | 1 | 2014 | 1565 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2010 | 552 | 0.070 |
Why?
|
| Immunotherapy | 2 | 2023 | 4446 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2010 | 548 | 0.070 |
Why?
|
| Lymphoma, Follicular | 1 | 2011 | 435 | 0.070 |
Why?
|
| Predictive Value of Tests | 6 | 2021 | 15078 | 0.070 |
Why?
|
| Neurofibromatosis 2 | 1 | 2010 | 380 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 2004 | 5181 | 0.070 |
Why?
|
| Transcription Factors | 3 | 2020 | 12207 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 1998 | 4561 | 0.070 |
Why?
|
| Neuroma, Acoustic | 1 | 2010 | 451 | 0.070 |
Why?
|
| Remission, Spontaneous | 1 | 2007 | 382 | 0.070 |
Why?
|
| Computer Simulation | 3 | 2016 | 6194 | 0.070 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 2 | 2006 | 277 | 0.070 |
Why?
|
| Meat | 1 | 2009 | 592 | 0.070 |
Why?
|
| Genes, p53 | 2 | 2005 | 755 | 0.070 |
Why?
|
| Time | 1 | 2008 | 542 | 0.070 |
Why?
|
| Gene Silencing | 2 | 2014 | 1539 | 0.070 |
Why?
|
| Random Allocation | 2 | 2023 | 2428 | 0.070 |
Why?
|
| Bacterial Infections | 2 | 2017 | 1401 | 0.070 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2004 | 685 | 0.070 |
Why?
|
| Chemokines, CXC | 1 | 2007 | 422 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2020 | 3587 | 0.060 |
Why?
|
| Edema | 1 | 2009 | 789 | 0.060 |
Why?
|
| Hospitals | 1 | 2019 | 3954 | 0.060 |
Why?
|
| Hyperventilation | 1 | 2005 | 81 | 0.060 |
Why?
|
| Genes, p16 | 1 | 2005 | 157 | 0.060 |
Why?
|
| Vision Disorders | 1 | 2012 | 1058 | 0.060 |
Why?
|
| Immunocompetence | 1 | 2005 | 136 | 0.060 |
Why?
|
| Incidence | 3 | 2019 | 20952 | 0.060 |
Why?
|
| Cooperative Behavior | 2 | 2010 | 1504 | 0.060 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2005 | 129 | 0.060 |
Why?
|
| Chemokine CXCL12 | 1 | 2007 | 465 | 0.060 |
Why?
|
| Drug Interactions | 3 | 2008 | 1460 | 0.060 |
Why?
|
| Glycolysis | 2 | 2020 | 829 | 0.060 |
Why?
|
| Cryoglobulinemia | 1 | 2004 | 87 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 3616 | 0.060 |
Why?
|
| Enzyme Activation | 3 | 2019 | 3702 | 0.060 |
Why?
|
| Kidney Function Tests | 1 | 2006 | 683 | 0.060 |
Why?
|
| Neoplasms, Second Primary | 1 | 2012 | 1062 | 0.060 |
Why?
|
| Phantoms, Imaging | 3 | 2020 | 2480 | 0.060 |
Why?
|
| Time Factors | 6 | 2019 | 40075 | 0.060 |
Why?
|
| Sulfonamides | 3 | 2008 | 1940 | 0.060 |
Why?
|
| Immunophenotyping | 1 | 2009 | 1880 | 0.060 |
Why?
|
| Genetic Heterogeneity | 2 | 2019 | 733 | 0.060 |
Why?
|
| Glucose | 1 | 2016 | 4398 | 0.060 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2004 | 335 | 0.060 |
Why?
|
| Child | 10 | 2021 | 77709 | 0.060 |
Why?
|
| Neuropsychological Tests | 3 | 2017 | 6994 | 0.060 |
Why?
|
| Herpesvirus 4, Human | 1 | 2009 | 1041 | 0.060 |
Why?
|
| Genomics | 2 | 2020 | 5717 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 3 | 2013 | 1799 | 0.060 |
Why?
|
| Syndecans | 1 | 2003 | 79 | 0.060 |
Why?
|
| Perfusion | 2 | 2019 | 1360 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2020 | 4839 | 0.060 |
Why?
|
| Meninges | 1 | 2005 | 190 | 0.060 |
Why?
|
| Cell Proliferation | 5 | 2018 | 10483 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 4386 | 0.060 |
Why?
|
| Neoplasm Transplantation | 2 | 2018 | 2086 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2020 | 841 | 0.050 |
Why?
|
| Child, Preschool | 6 | 2019 | 41005 | 0.050 |
Why?
|
| Stereotaxic Techniques | 1 | 2005 | 536 | 0.050 |
Why?
|
| Brain Stem Neoplasms | 1 | 2005 | 204 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2003 | 193 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2006 | 874 | 0.050 |
Why?
|
| Disease Models, Animal | 5 | 2019 | 18034 | 0.050 |
Why?
|
| Antineoplastic Protocols | 2 | 2015 | 50 | 0.050 |
Why?
|
| Syndecan-1 | 1 | 2003 | 165 | 0.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 4479 | 0.050 |
Why?
|
| Phenotype | 5 | 2020 | 16367 | 0.050 |
Why?
|
| Cell Movement | 2 | 2017 | 5218 | 0.050 |
Why?
|
| Seizures | 3 | 2008 | 2859 | 0.050 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2023 | 284 | 0.050 |
Why?
|
| Electronic Health Records | 1 | 2019 | 4468 | 0.050 |
Why?
|
| DNA Mismatch Repair | 2 | 2020 | 426 | 0.050 |
Why?
|
| DNA, Neoplasm | 2 | 2005 | 1758 | 0.050 |
Why?
|
| Infusions, Intravenous | 2 | 2014 | 2274 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 7282 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 1284 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2020 | 21748 | 0.050 |
Why?
|
| DNA Mutational Analysis | 3 | 2021 | 4185 | 0.050 |
Why?
|
| Interferon Regulatory Factors | 1 | 2003 | 270 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-met | 2 | 2018 | 578 | 0.050 |
Why?
|
| Movement Disorders | 1 | 2005 | 446 | 0.050 |
Why?
|
| Biological Availability | 1 | 2001 | 397 | 0.050 |
Why?
|
| Reproducibility of Results | 5 | 2023 | 19905 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2010 | 1856 | 0.050 |
Why?
|
| Creatinine | 1 | 2006 | 1919 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2013 | 5974 | 0.050 |
Why?
|
| Fibroblast Growth Factors | 1 | 2007 | 878 | 0.050 |
Why?
|
| Antibodies | 1 | 2009 | 2460 | 0.050 |
Why?
|
| Cytokines | 1 | 2015 | 7323 | 0.050 |
Why?
|
| Models, Genetic | 2 | 2009 | 3493 | 0.050 |
Why?
|
| Risk Factors | 2 | 2023 | 72296 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2011 | 8319 | 0.050 |
Why?
|
| Microcirculation | 2 | 2016 | 1287 | 0.050 |
Why?
|
| Vomiting | 2 | 2020 | 637 | 0.050 |
Why?
|
| Neprilysin | 1 | 2003 | 439 | 0.050 |
Why?
|
| Electronics | 1 | 2021 | 322 | 0.050 |
Why?
|
| Proportional Hazards Models | 5 | 2014 | 12356 | 0.050 |
Why?
|
| Logistic Models | 1 | 2015 | 13409 | 0.040 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2020 | 69 | 0.040 |
Why?
|
| Chromosome Deletion | 1 | 2005 | 1401 | 0.040 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2020 | 103 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 1572 | 0.040 |
Why?
|
| Viral Matrix Proteins | 1 | 2020 | 186 | 0.040 |
Why?
|
| International Cooperation | 4 | 2010 | 1420 | 0.040 |
Why?
|
| Proteoglycans | 1 | 2003 | 837 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2021 | 2618 | 0.040 |
Why?
|
| Meningitis, Aseptic | 1 | 1999 | 58 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2005 | 1132 | 0.040 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 380 | 0.040 |
Why?
|
| Emergency Service, Hospital | 1 | 2019 | 7658 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2004 | 1342 | 0.040 |
Why?
|
| Staphylococcal Protein A | 1 | 1998 | 40 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2022 | 326 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2001 | 1420 | 0.040 |
Why?
|
| Breast Neoplasms | 3 | 2020 | 20824 | 0.040 |
Why?
|
| Aging | 1 | 2018 | 8664 | 0.040 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 13991 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2005 | 2634 | 0.040 |
Why?
|
| Genes, myc | 1 | 2020 | 399 | 0.040 |
Why?
|
| HEK293 Cells | 2 | 2020 | 4208 | 0.040 |
Why?
|
| Adsorption | 1 | 1998 | 201 | 0.040 |
Why?
|
| Immune Sera | 1 | 1999 | 641 | 0.040 |
Why?
|
| Guidelines as Topic | 1 | 2005 | 1405 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 1872 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2011 | 9849 | 0.040 |
Why?
|
| Single-Cell Analysis | 2 | 2019 | 2182 | 0.040 |
Why?
|
| Myoclonus | 1 | 1998 | 104 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 779 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2018 | 66 | 0.040 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2018 | 112 | 0.040 |
Why?
|
| Dura Mater | 1 | 2020 | 291 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2004 | 2971 | 0.040 |
Why?
|
| Inhibitor of Differentiation Protein 1 | 1 | 2017 | 47 | 0.040 |
Why?
|
| Cell Survival | 2 | 2018 | 5882 | 0.040 |
Why?
|
| Age Distribution | 1 | 2004 | 2902 | 0.040 |
Why?
|
| Microsatellite Repeats | 1 | 2020 | 802 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 539 | 0.040 |
Why?
|
| Biological Therapy | 1 | 1999 | 138 | 0.040 |
Why?
|
| Immune System | 1 | 2023 | 806 | 0.040 |
Why?
|
| Benzylamines | 1 | 2018 | 223 | 0.040 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2016 | 806 | 0.040 |
Why?
|
| Cognition | 1 | 2015 | 6770 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2006 | 1239 | 0.040 |
Why?
|
| Heterocyclic Compounds | 1 | 2018 | 249 | 0.040 |
Why?
|
| Quinazolinones | 1 | 2019 | 221 | 0.040 |
Why?
|
| Benchmarking | 1 | 2024 | 1042 | 0.040 |
Why?
|
| Automation | 1 | 2019 | 584 | 0.040 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2018 | 270 | 0.040 |
Why?
|
| Glycoproteins | 1 | 2005 | 2266 | 0.040 |
Why?
|
| Respiratory Muscles | 1 | 1997 | 139 | 0.040 |
Why?
|
| Apoptosis | 3 | 2018 | 9724 | 0.040 |
Why?
|
| Cranial Nerve Diseases | 1 | 1997 | 112 | 0.040 |
Why?
|
| Folic Acid | 1 | 2023 | 1300 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2017 | 409 | 0.030 |
Why?
|
| 4-1BB Ligand | 1 | 2016 | 29 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2005 | 6366 | 0.030 |
Why?
|
| OX40 Ligand | 1 | 2016 | 51 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2020 | 4805 | 0.030 |
Why?
|
| Sciatic Nerve | 1 | 2000 | 607 | 0.030 |
Why?
|
| Pentosyltransferases | 1 | 2015 | 65 | 0.030 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2018 | 378 | 0.030 |
Why?
|
| Mucositis | 1 | 2017 | 101 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2020 | 1264 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2003 | 1434 | 0.030 |
Why?
|
| Drug Repositioning | 1 | 2018 | 230 | 0.030 |
Why?
|
| Genome-Wide Association Study | 2 | 2015 | 12262 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 6489 | 0.030 |
Why?
|
| Acrylamides | 1 | 2017 | 255 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2021 | 1200 | 0.030 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2004 | 1052 | 0.030 |
Why?
|
| Water | 1 | 2021 | 1395 | 0.030 |
Why?
|
| Plasma | 1 | 1998 | 575 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 1879 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2011 | 15520 | 0.030 |
Why?
|
| Anilides | 1 | 2017 | 408 | 0.030 |
Why?
|
| K562 Cells | 1 | 2016 | 635 | 0.030 |
Why?
|
| Receptors, Somatostatin | 1 | 2014 | 129 | 0.030 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 3611 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2014 | 323 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2015 | 351 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2019 | 1915 | 0.030 |
Why?
|
| Physical Examination | 1 | 2000 | 1237 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2010 | 7882 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2014 | 361 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2022 | 2016 | 0.030 |
Why?
|
| Infusions, Intraventricular | 1 | 2012 | 36 | 0.030 |
Why?
|
| Delayed-Action Preparations | 3 | 2002 | 968 | 0.030 |
Why?
|
| Acute Disease | 2 | 2010 | 7147 | 0.030 |
Why?
|
| Antigens | 1 | 1999 | 1466 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2018 | 1608 | 0.030 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2013 | 200 | 0.030 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2014 | 282 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 610 | 0.030 |
Why?
|
| Muscles | 1 | 1997 | 1614 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 2019 | 941 | 0.030 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 3771 | 0.030 |
Why?
|
| Vindesine | 1 | 2011 | 12 | 0.030 |
Why?
|
| Neurons | 2 | 2023 | 9340 | 0.030 |
Why?
|
| Area Under Curve | 2 | 2008 | 1655 | 0.020 |
Why?
|
| Emergencies | 1 | 1998 | 1170 | 0.020 |
Why?
|
| Reference Standards | 1 | 2015 | 1025 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 1941 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 1115 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2020 | 1373 | 0.020 |
Why?
|
| Valine | 1 | 2013 | 413 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2021 | 3203 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2020 | 14723 | 0.020 |
Why?
|
| Diet | 1 | 2009 | 7937 | 0.020 |
Why?
|
| Steroids | 1 | 1996 | 930 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2016 | 1254 | 0.020 |
Why?
|
| Ifosfamide | 1 | 2011 | 228 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 3646 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2019 | 2504 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 1641 | 0.020 |
Why?
|
| Caregivers | 1 | 2022 | 2095 | 0.020 |
Why?
|
| Frozen Sections | 1 | 2010 | 155 | 0.020 |
Why?
|
| Visual Acuity | 1 | 1999 | 2530 | 0.020 |
Why?
|
| Multivariate Analysis | 3 | 2010 | 12244 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 2012 | 0.020 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2010 | 204 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 1520 | 0.020 |
Why?
|
| Thromboembolism | 1 | 1996 | 987 | 0.020 |
Why?
|
| Massachusetts | 2 | 2014 | 8662 | 0.020 |
Why?
|
| Risk Assessment | 4 | 2015 | 23336 | 0.020 |
Why?
|
| Autopsy | 1 | 2013 | 1020 | 0.020 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 789 | 0.020 |
Why?
|
| Niacinamide | 1 | 2011 | 416 | 0.020 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2011 | 245 | 0.020 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2010 | 496 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 5867 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2016 | 1534 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1788 | 0.020 |
Why?
|
| Meat Products | 1 | 2009 | 99 | 0.020 |
Why?
|
| Molecular Biology | 1 | 2012 | 596 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2015 | 2715 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 625 | 0.020 |
Why?
|
| Monocytes | 1 | 2017 | 2596 | 0.020 |
Why?
|
| Geriatric Assessment | 1 | 2015 | 1372 | 0.020 |
Why?
|
| Blood Volume | 1 | 2009 | 565 | 0.020 |
Why?
|
| Autophagy | 1 | 2015 | 1297 | 0.020 |
Why?
|
| Endostatins | 1 | 2008 | 174 | 0.020 |
Why?
|
| Receptors, AMPA | 1 | 2009 | 332 | 0.020 |
Why?
|
| Integrins | 1 | 2012 | 846 | 0.020 |
Why?
|
| Transfection | 1 | 2015 | 5895 | 0.020 |
Why?
|
| Anxiety | 1 | 2022 | 4293 | 0.020 |
Why?
|
| Thrombospondins | 1 | 2008 | 198 | 0.020 |
Why?
|
| Diverticulitis | 1 | 2010 | 171 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2013 | 1169 | 0.020 |
Why?
|
| Metabolomics | 1 | 2015 | 1485 | 0.020 |
Why?
|
| RNA Interference | 1 | 2016 | 2890 | 0.020 |
Why?
|
| Visual Perception | 1 | 2016 | 1420 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2010 | 535 | 0.020 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2009 | 449 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2006 | 6598 | 0.020 |
Why?
|
| Genome, Human | 1 | 2020 | 4420 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2022 | 4245 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2014 | 2016 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 3505 | 0.020 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 2214 | 0.020 |
Why?
|
| Photons | 1 | 2010 | 588 | 0.020 |
Why?
|
| HIV Seronegativity | 1 | 2007 | 211 | 0.020 |
Why?
|
| Protein Binding | 1 | 2018 | 9384 | 0.020 |
Why?
|
| Hemodynamics | 1 | 2016 | 4196 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2006 | 380 | 0.020 |
Why?
|
| Learning | 1 | 2016 | 1711 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2006 | 475 | 0.020 |
Why?
|
| Selection Bias | 1 | 2008 | 371 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2023 | 10183 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2008 | 599 | 0.020 |
Why?
|
| Speech Perception | 1 | 2010 | 490 | 0.020 |
Why?
|
| Cell Line | 1 | 2020 | 16000 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2003 | 11486 | 0.020 |
Why?
|
| Attention | 1 | 2016 | 2397 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2009 | 1173 | 0.020 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2015 | 2305 | 0.020 |
Why?
|
| Nuclear Proteins | 2 | 2013 | 5856 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 5524 | 0.020 |
Why?
|
| Base Sequence | 2 | 2011 | 12797 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2016 | 3743 | 0.020 |
Why?
|
| Neutropenia | 1 | 2010 | 895 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2015 | 2897 | 0.020 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2010 | 770 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2015 | 3476 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2010 | 2879 | 0.010 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2005 | 529 | 0.010 |
Why?
|
| Vaccination | 1 | 2016 | 3279 | 0.010 |
Why?
|
| Carmustine | 1 | 2003 | 137 | 0.010 |
Why?
|
| Radiographic Image Enhancement | 1 | 2008 | 885 | 0.010 |
Why?
|
| Benzodiazepines | 1 | 2009 | 1101 | 0.010 |
Why?
|
| Inflammation | 1 | 2023 | 10637 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4253 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 2011 | 18111 | 0.010 |
Why?
|
| Internationality | 1 | 2008 | 1002 | 0.010 |
Why?
|
| Adipokines | 1 | 2005 | 320 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2013 | 4026 | 0.010 |
Why?
|
| Lectins | 1 | 2005 | 513 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2017 | 14561 | 0.010 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2010 | 1131 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2013 | 2917 | 0.010 |
Why?
|
| Depression | 1 | 2022 | 7759 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2006 | 1147 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 1178 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2016 | 5101 | 0.010 |
Why?
|
| Sample Size | 1 | 2005 | 845 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1996 | 9145 | 0.010 |
Why?
|
| Arachnoiditis | 1 | 2001 | 9 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 21833 | 0.010 |
Why?
|
| Anticoagulants | 1 | 1996 | 4600 | 0.010 |
Why?
|
| HIV Infections | 1 | 2007 | 16715 | 0.010 |
Why?
|
| Collagen | 1 | 2009 | 2688 | 0.010 |
Why?
|
| Autoantigens | 1 | 2005 | 892 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2006 | 1783 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2015 | 6542 | 0.010 |
Why?
|
| Research | 1 | 2008 | 1999 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2011 | 8436 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2003 | 624 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2006 | 1640 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2008 | 5077 | 0.010 |
Why?
|
| Decision Making | 1 | 2012 | 3888 | 0.010 |
Why?
|
| United States | 2 | 2009 | 69872 | 0.010 |
Why?
|
| Treatment Refusal | 1 | 2001 | 421 | 0.010 |
Why?
|
| Infant | 1 | 2019 | 35134 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3921 | 0.010 |
Why?
|
| Risk | 1 | 2009 | 9688 | 0.010 |
Why?
|
| Epilepsy | 1 | 2012 | 3310 | 0.010 |
Why?
|
| Spinal Cord Compression | 1 | 1998 | 235 | 0.010 |
Why?
|
| Cerebral Hemorrhage | 1 | 2007 | 2647 | 0.010 |
Why?
|
| Testis | 1 | 1999 | 804 | 0.010 |
Why?
|
| Survivors | 1 | 2005 | 2291 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1999 | 4320 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 15535 | 0.010 |
Why?
|
| Epitopes | 1 | 1999 | 2571 | 0.010 |
Why?
|
| Health Status | 1 | 2005 | 4034 | 0.010 |
Why?
|
| Cerebrovascular Disorders | 1 | 1998 | 1504 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1999 | 13814 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1999 | 13035 | 0.000 |
Why?
|
| Rats | 1 | 1999 | 24252 | 0.000 |
Why?
|